Role of PC-1 in the etiology of insulin resistance

Annals of the New York Academy of Sciences

Volumn 892, Issue , 1999, Pages 204-222

  Goldfine, Ira D ^a,d   Maddux, Betty A ^a   Youngren, Jack F ^a   Trischitta, Vincenzo ^b   Frittitta, Lucia ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Divisione e Unita di Ric di E   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UCSF Box 1616   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; INSULIN; INSULIN RECEPTOR; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE;

ADIPOSE TISSUE; CASE REPORT; CELL ACTIVATION; CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0032778487     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07797.x     Document Type: Conference Paper

References (70)

1. 1. Kahn, C. R. 1994. Insulin action, diabetogenes, and the cause of type 2 diabetes. Diabetes 43: 1066-1084.
2. 2. Haffner, S. M. et al. 1990. Incidence of type 2 diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity and body fat distribution. Diabetes 39: 283-288.
3. 3. Martin, B. C. et al. 1992. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340: 925-929.
4. 4. Reaven, G. M. 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
5. 5. Ruderman, N. et al. 1998. The metabolically obese, normal-weight individual revisited. Diabetes 47: 699-713.
6. 6. Reaven, G. M. 1993. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu. Rev. Med. 44: 121-131.
7. 7. Bonora, E. et al. 1998. Prevalence of insulin resistance in metabolic disorders; The Bruneck Study. Diabetes 47: 1643-1649.
8. 8. Mykkänen, L. et al. 1997. Low insulin sensitivity is associated with clustering of cardiovascular risk factors. Am. J. Epidemiol. 146: 315-321.
9. 9. Després, J-P. et al. 1996. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334: 952-957.
10. 10. DeFronzo, R. A., E. Ferrannini & V. Koivisto. 1983. New concepts in the pathogenesis and treatment of non-insulin dependent diabetes mellitus. Am. J. Med. 74: 52.
11. 11. Olefsky, J. M. 1980. Lilly lecture: Insulin resistance and insulin action. Diabetes 30: 148-158.
12. 12. Youngren, J. F. & I. D. Goldfine. 1997. The molecular basis of insulin resistance. Sci. Med. 4: 18-27.
13. 13. Bogardus, C. et al. 1989. Distribution of in vivo insulin action in Pima Indians as mixture of three normal distributions. Diabetes 38: 1423-1431.
14. 14. Taylor, S. I. 1992. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41: 1473-1477.
15. 15. Bogardus, C. et al. 1985. Relationship between degree of obesity and in vivo insulin action in man. Am. J. Physiol. 248: E286-E291.
16. 16. Clausen, J. O. et al. 1996. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. J. Clin. Invest. 98: 1195-1209.
17. 17. Youngren J. F., I. D. Goldfine & R. E. Pratley. 1997. Decreased muscle insulin receptor kinase correlates with insulin resistance in normoglycemic Pima Indians. Am. J. Physiol. 273: E276-E283.
18. 18. Rosenthal, M. et al. 1983. Demonstration of a relationship between level of physical training and insulin-stimulated glucose utilization in normal humans. Diabetes 32: 408-411.
19. 19. Carey, D. G. et al. 1996. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 46: 456-462.
20. 20. Goldfine, I. D. 1987. The insulin receptor: molecular biology and transmembrane signaling. Endocr. Rev. 8: 235-255.
21. 21. Roth, R. A. & D. J. Cassell. 1983. Insulin receptor: evidence that it is a protein kinase. Science 219: 299-301.
22. 22. Kahn, C. R. & M. F. White. 1988. The insulin receptor and the molecular mechanism of insulin action. J. Clin. Invest. 82: 1551-1553.
23. 23. White, M. F. 1994. The IRS-1 signaling system. Curr. Opin. Genet. Dev. 4: 47-54.
24. 24. Summers, S. A. et al. 1998. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell Biol. 18: 5457-5464.
25. 25. Caro, J. F. et al. 1987. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin dependent diabetes. J. Clin. Invest. 79: 1330-1337.
26. 26. Nyomba, B. L. et al. 1990. Insulin-sensitive tyrosine kinase: relationship with in vivo insulin action in humans. Am. J. Physiol. 258: E964-E974.
27. 27. Maegawa, H. et al. 1991. Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in non-obese subjects with NIDDM. Diabetes 40: 815-819.
28. 28. Obermaier-Kusser, B. et al. 1989. A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus. J. Biol. Chem. 264: 9497-9504.
29. 29. Scheck, S. H. et al. 1992. Effects of NIDDM on glucose transport system in human skeletal muscle. Diabetes Res. 16: 111-119.
30. 30. Arner, P. et al. 1987. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 437-440.
31. 31. Nolan, J. J. et al. 1994. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of non-insulin-dependent diabetes mellitus and obesity. J. Clin. Endocrinol. Metab. 78: 471-477.
32. 32. Freidenberg, G. R. et al. 1987. Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic subjects. J. Clin. Invest. 79: 240-250.
33. 33. Bollag, G. E. et al. 1986. Protein kinase C directly phosphorylates the insulin receptor in vitro and reduces its protein tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 83: 5822-5824.
34. 34. Handberg, A. et al. 1993. Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first degree relatives patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36: 668-674.
35. 35. Dunaif, A. et al. 1995. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J. Clin. Invest. 96: 801-810.
36. 36. Takayama, S. et al. 1987. Alterations in insulin receptor autophosphorylation in insulin resistance: correlation with altered sensitivity to glucose transport and antilipolysis to insulin. J. Clin. Endocrinol. Metab. 66: 992-999.
37. 37. Grasso, G. et al. 1995. Insulin receptor tyrosine kinase activity is altered in both muscle and adipose tissue from nonobese normoglycemic insulin resistant subjects. Diabetologia 38: 55-61.
38. 38. Frittitta, L. et al. 1996. PC-1 content in skeletal muscle of non-obese, non-diabetic subjects, relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia 39: 1190-1195.
39. 39. Frittitta, L. et al. 1997. Increased adipose tissue PC-1 protein content, but not TNF-α gene expression, is associated to a reduction of both whole body insulin sensitivity and insulin receptor tyrosine kinase activity. Diabetologia 40: 282-289.
40. 40. Seino, S. & G. I. Bell. 1989. Alternative splicing of human insulin receptor messenger RNA. Biochem. Biophys. Res. Commun. 159: 312-316.
41. 41. Mosthaf, L. et al. 1991. Altered expression of insulin receptor types A and B in the skeletal muscle of non-insulin-dependent diabetes mellitus patients. Proc. Natl. Acad. Sci. USA 88: 4728-4730.
42. 42. Hansen, T. et al. 1993. Expression of insulin receptor spliced variants and their functional correlates in muscle from patients with non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 77: 1500-1505.
43. 43. Kosaki, A. et al. 1995. The B isoform of the insulin receptor signals more efficiently than the A isoform in Hep G2 cells. J. Biol. Chem. 270: 20816-20823.
44. 44. Kellerer, M. et al. 1995. Mechanism of insulin receptor kinase inhibition in non-insulin-dependent diabetes mellitus patients: phosphorylation of serine 1327 or threonine 1348 is unaltered. J. Clin. Invest. 96: 6-11.
45. 45. Hotamisligal, G. S. et al. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA 91: 4854-4858.
46. 46. Saghizadeh, M. et al. 1996. The expression of TNFα by human muscle: relationship to insulin resistance. J. Clin. Invest. 77: 1111-1116.
47. 47. Fofei, S. et al. 1996. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881-885.
48. 48. Goldstein, B. J. et al. 1998. Regulation of insulin action by protein tyrosine phosphatases. Vitam. Horm. 54: 67-96.
49. 49. Van Driel, I. R. & J. W. Goding. 1987. Plasma cell membrane glycoprotein PC-1. J. Biol. Chem. 262: 4882-4889.
50. 50. Harahap, R. & J. W. Goding. 1988. Distribution of PC-1 in non lymphoid tissues. J. Immunology 141: 2317-2337.
51. 51. Buckley, M. F. et al. 1990. Plasma cell membrane glycoprotein PC-1 cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J. Biol. Chem. 265: 17506-17512.
52. 52. Rebbe, N. F. et al. 1991. Identification of nucleotide pyrophosphatase/alkaline phosphodiesterase I activity associated with the mouse plasma cell differentiation antigen PC-1. Proc. Natl. Acad. Sci. USA 88: 5192-5197.
53. 53. Rebbe, N. F., B. D. Tong & S. Hickman. 1993. Expression of nucleotide pyrophosphatase and alkaline phosphodiesterase I activities of PC-1, the murine plasma cell antigen. Mol. Immunol. 30: 87-96.
54. 54. Yoshida, H., S. Fukui & I. Yamashina. 1983. Substrate specificity of a nucleotide pyrophosphatase responsible for the breakdown of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) from human placenta. J. Biochem. 93: 1641-1653.
55. 55. Goding, J. W. et al. 1998. Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. Immunol. Rev. 161: 11-26.
56. 56. Grupe, J. et al. 1995. Inhibition of insulin receptor phosphorylation by PC-1 is not mediated by the hydrolysis of adenosine triphosphate or the generation of adenosine. J. Biol. Chem. 270: 22085-22088.
57. 57. Oda, Y. et al. 1991. The plasma cell membrane glycoprotein, PC-1, is a threonine specific protein kinase stimulated by acidic fibroblast growth factor. J. Biol. Chem. 266: 16791-16798.
58. 58. Duggirala, R. et al. 1996. Evidence for linkage between fasting and 2-hr plasma glucose levels and regions on chromosomes 6 and 11 in Mexican Americans [abstr.]. Diabetes 45 (Suppl. 2): 228A.
59. 59. Temple, I. K. et al. 1996. Further evidence for an imprinted gene for neonatal diabetes localized to chromosome 6q22-q23. Hum. Mol. Genet. 5: 1117-1121.
60. 60. Kawagoe, H. et al. 1995. Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphotase gene (PDNP2). Genomics 30: 380-384.
61. 61. Murata, J. et al. 1994. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterase. J. Biol. Chem. 269: 30479-30484.
62. 62. Deisler, H., F. Lottspeich & M. F. Rajewsky. 1995. Affinity purification and cDNA cloning of rat neural differentiation and tumor cell surface antigen gp130 RB13-6 reveals relationship to human and murine PC-1. J. Biol. Chem. 270: 9849-9855.
63. 63. Maddux, B. A. et al. 1995. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes. Nature. 373: 448-451.
64. 64. Sbraccia, P. et al. 1991. Production of an inhibitor of insulin receptor tyrosine kinase in fibroblasts from a patient with insulin resistance and NIDDM. Diabetes 40: 295-299.
65. 65. Frittitta, L. et al. 1998. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in non-diabetic subjects. Evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 47: 1095-1100.
66. 66. Rousseau, G. G. et al. 1980. Glucocorticoid hormones increase the activity of plasma membrane alkaline phosphodiesterase I in rat hepatoma cells. Proc. Natl. Acad. Sci. USA 77: 1005-1009.
67. 67. Deterre, P. et al. 1996. Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1. J. Immunol. 157: 1381-1388.
68. 68. Stefan, C., W. Stalmans & M. Bollen. 1998. Growth-related expression of the ectonucleotide pyrophosphatase PC-1 in rat liver. Hepatology 28: 1497-1503.
69. 69. Milazzo, G. et al. 1992. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 52: 3924-3930.
70. 70. Kumakura, S., B. A. Maddux & C. K. Sung. 1998. Overexpression of membrane glycoprotein PC-1 can influence insulin action at a post-receptor site. J. Cell. Biol. 68: 366-377.